Immune Correlates May Indicate Responsiveness to Ipilimumab in mCRPC
A subset of patients with metastatic castration-resistant prostate cancer who have low tumor mutational burden may benefit from checkpoint inhibition with ipilimumab if the tumor has a high density of CD8-positive T cells and increased interferon-interferon gamma signaling.
Source: OncLive